

Table 1. Position on Rosiglitazone Safety and Conflicted Financial Relationships.

Conflicted financial relationship	Risk of Myocardial Infarction with Rosiglitazone				Use of Rosiglitazone			
	Favorable N = 31	Neutral N = 84	Unfavorable N = 65	Rate Ratio (95% CI)*	Favorable N = 29	Neutral N = 129	Unfavorable N = 44	Rate Ratio (95% CI)*
Any manufacturer	29 (94%)	32 (38%)	18 (28%)	3.38 (2.26 to 5.06)	23 (88%)	46 (40%)	10 (26%)	3.36 (1.94 to 5.83)
Rosiglitazone manufacturer**	27 (87%)	25 (24%)	13 (20%)	4.29 (2.63 to 7.02)	21 (81%)	30 (26%)	9 (24%)	3.60 (2.00 to 6.48)
Pioglitazone manufacturer**	20 (65%)	31 (30%)	14 (22%)	3.96 (2.45 to 6.39)	19 (73%)	30 (26%)	10 (26%)	3.28 (1.88 to 5.73)
None	2 (6%)	52 (62%)	47 (72%)		3 (12%)	70 (60%)	28 (74%)	

*comparing favorable vs. unfavorable views; **these are not mutually exclusive categories.